Journal
FUTURE ONCOLOGY
Volume 10, Issue 14, Pages 2177-2187Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/fon.14.152
Keywords
COX-2; celecoxib; cyclooxygenase-2; interferon; NSAID; PGE-2; prostaglandin; renal cell carcinoma; sunitinib
Categories
Funding
- Military Institute of Medicine [187]
Ask authors/readers for more resources
COX-2 plays a crucial pathophysiological role in the development of renal cell cancer (RCC). Recently, it has been shown that COX-2 inhibition enhances the efficacy of immunotherapy and tyrosine kinase inhibitor-based treatment. At the same time, molecular analyses revealed particular contribution of a COX-2 product - prostaglandin E2 (PGE2) - in RCC development. PGE2 was shown to activate Akt/RGC2/RalA signaling cascade in RCC cells. It also demonstrated upregulation of the expression of HIF-1 and PI3K/Akt/mTOR signaling pathway. All together, these data suggest that targeted anti-PGE2 therapies may offer an interesting therapeutic option for RCC patients in the future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available